GI CONNECT has summarised the highlights from the ASCO GI 2020 meeting for you. Dr Samuel Klempner (USA) provides the highlights on upper GI.
GI CONNECT has summarised the highlights from the ASCO GI 2020 meeting for you. Dr Samuel Klempner (USA) provides the highlights on upper GI.
Dr. Klempner is an Associate Professor at Massachusetts General Hospital and Harvard Medical School and leads the gastric and oesophageal programme. His clinical and translational research is centred on cancer genomics, acquired resistance to targeted therapies and the intersection of genomics and immune mediated therapies to identify novel therapeutic approaches and biomarkers in gastroesophageal cancers. He serves on the NRG non-colorectal committee, co-chairs the NCI oesophagogastric task force, and is on the NCCN guideline committees for gastric and oesophageal cancers. His work is supported by Stand Up 2 Cancer, NCI/NIH, AACR, the Degregorio Foundation, and The Gastric Cancer Foundation and Gateway for Cancer Research. He is active in gastric and oesophageal cancer outreach and patient advocacy.
Astellas, AstraZeneca, BMS, Coherus, Daiichi-Sankyo, Eli Lilly, Merck, Novartis, Nuvalent Therapuetics and Sanofi.
Module 4: Treatment strategies for patients ineligible for IO or those with progression on IO
Expert opinion on the latest practice-changing data
Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer
Experți de renume din domeniul medical își împărtășesc perspectivele. Navigați în secțiuni pentru a selecta un episod al podcastului
Improving the survival of patients with relapsed/refractory multiple myeloma